Food and Drug Administration approved a GLP-1 drug, Wegovy, for use by adults with obesity or a weight-related condition
The primary mechanism of action involves: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels without causing hypoglycaemia when glucose levels are normal [3] [4] Suppressing glucagon release , thereby reducing glucose production by the liver Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake When administered as medication, GLP-1 receptor agonists mimic these natural effects but with enhanced duration and potency
Rapid weight loss can also affect sebaceous glands
In fact, according to a 2021 survey, 73 percent of women aged 40 to 65 were not currently treating their menopause symptoms
Combined immunohistochemistry and RNAscope following compounds dosing Male DIO mice were divided into 6 treatment groups (n = 8/group)
Seek immediate medical help for an allergic reaction
